{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:34:12Z","timestamp":1793522052301,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pronectins\u2122 are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer. We describe here the in vitro and in vivo activity of a Pronectin\u2122 AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3\u03b5) against Epithelial Ovarian Cancer (EOC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>pAXLxCD3\u03b5 T-cell mediated cytotoxicity was evaluated by flow cytometry and bioluminescence. pAXLxCD3\u03b5 mediated T-cell infiltration, activation and proliferation were assessed by immunofluorescence microscopy and by flow cytometry. Activity of pAXLxCD3\u03b5 was also investigated in combination with poly-ADP ribose polymerase inhibitors (PARPi). In vivo\u00a0antitumor activity of pAXLxCD3\u03b5 was evaluated in\u00a0immunocompromised (NSG) mice bearing intraperitoneal or subcutaneous EOC xenografts and immunologically reconstituted with human peripheral blood mononuclear cells (PBMC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>pAXLxCD3\u03b5 induced dose-dependent cytotoxicity by activation of T lymphocytes against EOC cells, regardless of their histologic origin. The addition\u00a0of PARPi to cell cultures enhanced pAXLxCD3\u03b5 cytotoxicity. Importantly,\u00a0in vivo, pAXLxCD3\u03b5 was highly effective against EOC xenografts in two different NSG mouse models, by inhibiting the growth of tumor cells in ascites and subcutaneous xenografts. This effect translated into a significantly prolonged survival of treated animals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>pAXLxCD3\u03b5 is an active therapeutics against EOC cells providing a rational for its development as a novel agent in this still incurable disease. The preclinical validation of a first-in-class agent opens the way to the development of a new 14Fn3-based scaffold platform for the generation of innovative immune therapeutics against cancer.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-023-04101-x","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T19:01:42Z","timestamp":1683226902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Pronectin\u2122 AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3\u03b5) for ovarian cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Caterina","family":"Riillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Poler\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Juli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Hokanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Odineca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Grillone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Ascrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basilio","family":"Caparello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Caracciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-6787","authenticated-orcid":false,"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"4101_CR1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12665\/J114.Jha","volume":"11","author":"CS Mintz","year":"2013","unstructured":"Mintz CS, Crea R. Protein scaffolds: the next generation of protein therapeutics? Bioproc Int. 2013;11:40\u20138.","journal-title":"Bioproc Int"},{"key":"4101_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1755-1536-4-21","volume":"4","author":"WS To","year":"2011","unstructured":"To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 2011;4:21.","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"4","key":"4101_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1006\/jmbi.1998.2238","volume":"284","author":"A Koide","year":"1998","unstructured":"Koide A, Bailey CW, Huang X, Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol. 1998;284(4):1141\u201351.","journal-title":"J Mol Biol"},{"issue":"3","key":"4101_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/cells9030610","volume":"9","author":"PG Chandler","year":"2020","unstructured":"Chandler PG, Buckle AM. Development and differentiation in monobodies based on the fibronectin type 3 domain. Cells. 2020;9(3):610.","journal-title":"Cells"},{"key":"4101_CR5","unstructured":"Cappuccilli G, Crea R, Shen R, Hokanson CA, Kirk PB, Liston DR, inventors; Protelica Inc, assignee. Universal fibronectin type III binding-domain libraries. United States patent US 9,376,483. 28 Jun 2016."},{"issue":"2","key":"4101_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jmb.2011.12.019","volume":"415","author":"A Koide","year":"2012","unstructured":"Koide A, Wojcik J, Gilbreth RN, Hoey RJ, Koide S. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol. 2012;415(2):393\u2013405.","journal-title":"J Mol Biol"},{"issue":"10","key":"4101_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/protein\/gzu016","volume":"27","author":"MD Diem","year":"2014","unstructured":"Diem MD, Hyun L, Yi F, Hippensteel R, Kuhar E, Lowenstein C, et al. Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions. Protein Eng Des Sel. 2014;27(10):419\u201329.","journal-title":"Protein Eng Des Sel"},{"issue":"4","key":"4101_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jmb.2007.02.029","volume":"368","author":"D Lipovsek","year":"2007","unstructured":"Lipovsek D, Lippow SM, Hackel BJ, Gregson MW, Cheng P, Kapila A, et al. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol. 2007;368(4):1024\u201341.","journal-title":"J Mol Biol"},{"key":"4101_CR9","volume":"147","author":"O Hantschel","year":"2017","unstructured":"Hantschel O. Monobodies as possible next-generation protein therapeutics\u2014a perspective. Swiss Med Wkly. 2017;147: w14545.","journal-title":"Swiss Med Wkly"},{"issue":"8","key":"4101_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","volume":"8","author":"CY Slaney","year":"2018","unstructured":"Slaney CY, Wang P, Darcy PK, Kershaw MH. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 2018;8(8):924\u201334.","journal-title":"Cancer Discov"},{"key":"4101_CR11","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276.","journal-title":"Front Immunol"},{"issue":"2","key":"4101_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002026","volume":"9","author":"D Caracciolo","year":"2021","unstructured":"Caracciolo D, Riillo C, Ballerini A, Gaipa G, Lhermitte L, Rossi M, et al. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. J Immunother Cancer. 2021;9(2): e002026.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"4101_CR13","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.3390\/cancers14122886","volume":"14","author":"C Riillo","year":"2022","unstructured":"Riillo C, Caracciolo D, Grillone K, Polera N, Tuccillo FM, Bonelli P, et al. A novel bispecific T-cell engager (CD1a x CD3epsilon) BTCE is effective against cortical-derived T cell acute lymphoblastic leukemia (T-ALL) cells. Cancers (Basel). 2022;14(12):2886.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"4101_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13046-019-1354-1","volume":"38","author":"S Yu","year":"2019","unstructured":"Yu S, Zhang J, Yan Y, Yao X, Fang L, Xiong H, et al. A novel asymmetrical anti-HER2\/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019;38(1):355.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4101_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-020-01564-4","volume":"39","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zong H, Han L, Xie Y, Jiang H, Gilly J, et al. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. J Exp Clin Cancer Res. 2020;39(1):87.","journal-title":"J Exp Clin Cancer Res"},{"key":"4101_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13046-015-0241-7","volume":"34","author":"F Ferrari","year":"2015","unstructured":"Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, et al. Solitomab, an EpCAM\/CD3 bispecific antibody construct (BiTE(R)), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res. 2015;34:123.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4101_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-017-1244-2","volume":"15","author":"M Graciotti","year":"2017","unstructured":"Graciotti M, Berti C, Klok HA, Kandalaft L. The era of bioengineering: how will this affect the next generation of cancer immunotherapy? J Transl Med. 2017;15(1):142.","journal-title":"J Transl Med"},{"key":"4101_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1479-5876-11-147","volume":"11","author":"V Lavoue","year":"2013","unstructured":"Lavoue V, Thedrez A, Leveque J, Foucher F, Henno S, Jauffret V, et al. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med. 2013;11:147.","journal-title":"J Transl Med"},{"issue":"1","key":"4101_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12967-020-02295-y","volume":"18","author":"Y Dabi","year":"2020","unstructured":"Dabi Y, Huchon C, Ouldamer L, Bendifallah S, Collinet P, Bricou A, et al. Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival. J Transl Med. 2020;18(1):134.","journal-title":"J Transl Med"},{"issue":"7","key":"4101_CR20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/cancers13071521","volume":"13","author":"M Wium","year":"2021","unstructured":"Wium M, Ajayi-Smith AF, Paccez JD, Zerbini LF. The role of the receptor tyrosine kinase Axl in carcinogenesis and development of therapeutic resistance: an overview of molecular mechanisms and future applications. Cancers (Basel). 2021;13(7):1521.","journal-title":"Cancers (Basel)."},{"key":"4101_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/OTT.S150952","volume":"11","author":"S Zhang","year":"2018","unstructured":"Zhang S, Xu XS, Yang JX, Guo JH, Chao TF, Tong Y. The prognostic role of Gas6\/Axl axis in solid malignancies: a meta-analysis and literature review. Onco Targets Ther. 2018;11:509\u201319.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"4101_CR22","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/cancers12071850","volume":"12","author":"M Tanaka","year":"2020","unstructured":"Tanaka M, Siemann DW. Gas6\/Axl signaling pathway in the tumor immune microenvironment. Cancers (Basel). 2020;12(7):1850.","journal-title":"Cancers (Basel)."},{"issue":"18","key":"4101_CR23","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.3390\/ijms22189953","volume":"22","author":"M Tanaka","year":"2021","unstructured":"Tanaka M, Siemann DW. Therapeutic targeting of the Gas6\/Axl signaling pathway in cancer. Int J Mol Sci. 2021;22(18):9953.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"4101_CR24","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.1158\/0008-5472.CAN-10-1267","volume":"70","author":"EB Rankin","year":"2010","unstructured":"Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Can Res. 2010;70(19):7570\u20139.","journal-title":"Can Res"},{"key":"4101_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.omtn.2017.06.023","volume":"9","author":"P Kanlikilicer","year":"2017","unstructured":"Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, et al. Therapeutic targeting of AXL receptor tyrosine kinase inhibits tumor growth and intraperitoneal metastasis in ovarian cancer models. Mol Ther Nucleic Acids. 2017;9:251\u201362.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"4101_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41401-020-00546-8","volume":"42","author":"M Tian","year":"2021","unstructured":"Tian M, Chen XS, Li LY, Wu HZ, Zeng D, Wang XL, et al. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis. Acta Pharmacol Sin. 2021;42(7):1180\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4101_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/genbio.2022.0034","volume":"2","author":"Y Fang","year":"2023","unstructured":"Fang Y, Imoukhuede PI. Axl and vascular endothelial growth factor receptors exhibit variations in membrane localization and heterogeneity across monolayer and spheroid high-grade serous ovarian cancer models. GEN Biotechnol. 2023;2(1):43\u201356.","journal-title":"GEN Biotechnol"},{"issue":"1","key":"4101_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153.","journal-title":"Mol Cancer"},{"key":"4101_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123184","author":"CA Hokanson","year":"2022","unstructured":"Hokanson CA, Zacco E, Cappuccilli G, Odineca T, Crea R. AXL-receptor targeted 14FN3 based single domain proteins (Pronectins\u2122) from 3 synthetic human libraries as components for exploring novel bispecific constructs against solid tumors. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10123184.","journal-title":"Biomedicines"},{"issue":"17","key":"4101_CR30","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.3390\/cancers13174365","volume":"13","author":"D Caracciolo","year":"2021","unstructured":"Caracciolo D, Riillo C, Juli G, Scionti F, Todoerti K, Polera N, et al. miR-22 modulates lenalidomide activity by counteracting MYC addiction in multiple myeloma. Cancers (Basel). 2021;13(17):4365.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"4101_CR31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00280-009-0957-1","volume":"64","author":"D Cosco","year":"2009","unstructured":"Cosco D, Bulotta A, Ventura M, Celia C, Calimeri T, Perri G, et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother Pharmacol. 2009;64(5):1009\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4101_CR32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2008.07387.x","volume":"143","author":"P Neri","year":"2008","unstructured":"Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol. 2008;143(4):520\u201331.","journal-title":"Br J Haematol"},{"issue":"4","key":"4101_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0192-0561(92)90116-3","volume":"14","author":"JW Hadden","year":"1992","unstructured":"Hadden JW, Ongradi J, Specter S, Nelson R, Sosa M, Monell C, et al. Methyl inosine monophosphate: a potential immunotherapeutic for early human immunodeficiency virus (HIV) infection. Int J Immunopharmacol. 1992;14(4):555\u201363.","journal-title":"Int J Immunopharmacol"},{"issue":"1","key":"4101_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12967-021-03073-0","volume":"19","author":"J Meng","year":"2021","unstructured":"Meng J, Peng J, Feng J, Maurer J, Li X, Li Y, et al. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. J Transl Med. 2021;19(1):415.","journal-title":"J Transl Med"},{"issue":"1","key":"4101_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12967-020-02613-4","volume":"18","author":"R Sheta","year":"2020","unstructured":"Sheta R, Bachvarova M, Plante M, Renaud MC, Sebastianelli A, Gregoire J, et al. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. J Transl Med. 2020;18(1):439.","journal-title":"J Transl Med"},{"key":"4101_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12967-014-0347-2","volume":"12","author":"K Urbanska","year":"2014","unstructured":"Urbanska K, Lynn RC, Stashwick C, Thakur A, Lum LG, Powell DJ Jr. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J Transl Med. 2014;12:347.","journal-title":"J Transl Med"},{"issue":"2","key":"4101_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4161\/mabs.2.2.11221","volume":"2","author":"R Linke","year":"2010","unstructured":"Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010;2(2):129\u201336.","journal-title":"MAbs"},{"issue":"9","key":"4101_CR38","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"4101_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-022-03285-y","volume":"20","author":"ST Nobari","year":"2022","unstructured":"Nobari ST, Nojadeh JN, Talebi M. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med. 2022;20(1):82.","journal-title":"J Transl Med"},{"issue":"1","key":"4101_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4101_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cancers13020287","volume":"13","author":"J Middelburg","year":"2021","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers. 2021;13(2):287.","journal-title":"Cancers"},{"key":"4101_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.756225","volume":"11","author":"HY Son","year":"2021","unstructured":"Son HY, Jeong HK. Immune evasion mechanism and AXL. Front Oncol. 2021;11: 756225.","journal-title":"Front Oncol"},{"key":"4101_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.414","author":"S Ramalingam","year":"2019","unstructured":"Ramalingam S, Lopez J, Mau-Sorensen M, Thistlethwaite F, Piha-Paul S, Gadgeel S, et al. OA02.05 first-in-human phase 1\/2 trial of anti-AXL antibody-drug conjugate (ADC) Enapotamab Vedotin (EnaV) in advanced NSCLC. J Thorac Oncol. 2019. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.414.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4101_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cts.12869","volume":"14","author":"M Arbitrio","year":"2021","unstructured":"Arbitrio M, Scionti F, Di Martino MT, Caracciolo D, Pensabene L, Tassone P, et al. Pharmacogenomics biomarker discovery and validation for translation in clinical practice. Clin Transl Sci. 2021;14(1):113\u20139.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"4101_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ht7040040","volume":"7","author":"M Arbitrio","year":"2018","unstructured":"Arbitrio M, Di Martino MT, Scionti F, Barbieri V, Pensabene L, Tagliaferri P. Pharmacogenomic profiling of ADME gene variants: current challenges and validation perspectives. High Throughput. 2018;7(4):40.","journal-title":"High Throughput"},{"issue":"2","key":"4101_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi Triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Can Res. 2019;79(2):311\u20139.","journal-title":"Can Res"},{"issue":"10","key":"4101_CR47","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1002\/ijc.33038","volume":"147","author":"D Caracciolo","year":"2020","unstructured":"Caracciolo D, Riillo C, Arbitrio M, Di Martino MT, Tagliaferri P, Tassone P. Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. Int J Cancer. 2020;147(10):2658\u201368.","journal-title":"Int J Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04101-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04101-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04101-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T03:24:38Z","timestamp":1702351478000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04101-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4101"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04101-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experimental animal procedures and protocols had been approved by the Magna Graecia University IRB and conducted according to protocols approved by the National Directorate of Veterinary Services (Italy).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors (1) declare no competing financial interests. R.Crea, C.Hokanson, and T.Odineca are associated with Protelica, Inc, USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}